trazodone has been researched along with carbamazepine in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (9.09) | 18.7374 |
| 1990's | 6 (27.27) | 18.2507 |
| 2000's | 5 (22.73) | 29.6817 |
| 2010's | 8 (36.36) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Creveling, CR; Daly, JW; Lewandowski, GA; McNeal, ET | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Boriss, H; Braggio, S; Corbioli, S; Fontana, S; Helmdach, L; Longhi, R; Schiller, J; Vinco, F | 1 |
| Chang, G; Di, L; Huang, Y; Lin, Z; Liston, TE; Scott, DO; Troutman, MD; Umland, JP | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Schneider, LS; Sobin, PB | 1 |
| Anfinson, T | 1 |
| Tasini, M | 1 |
| Brawman-Mintzer, O; Mintzer, JE | 1 |
| Ishida, M; Kaneko, S; Mihara, K; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K | 1 |
| Kaneko, S; Ohkubo, T; Osanai, T; Otani, K; Sugawara, K; Yasui, N | 1 |
| Delgado, RG; Peña, MF; Romero, AS | 1 |
| Durán-Quintana, JA; García-Delgado, R; Mayordomo-Aranda, A; Sánchez-Romero, A | 1 |
| Dhindsa, RS; Goldstein, DB; Krizay, DK; Vasavda, C; Zoghbi, AW | 1 |
3 review(s) available for trazodone and carbamazepine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia.
Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Buspirone; Carbamazepine; Dementia; Humans; Lithium; Neurotransmitter Uptake Inhibitors; Selegiline; Serotonin; Trazodone | 1992 |
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.
Topics: Aged; Aggression; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Buspirone; Carbamazepine; Clozapine; Combined Modality Therapy; Decision Trees; Dementia; Humans; Ondansetron; Psychomotor Agitation; Serotonin; Trazodone | 1996 |
19 other study(ies) available for trazodone and carbamazepine
| Article | Year |
|---|---|
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Anesthetics, Local; Animals; Batrachotoxins; Calcium Channel Blockers; Cyclic AMP; Guinea Pigs; Histamine H1 Antagonists; In Vitro Techniques; Ion Channels; Neurotoxins; Sodium; Tranquilizing Agents; Tritium | 1985 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
Topics: Absorption; Albumins; Animals; Brain; Brain Chemistry; Cell Membrane; Chromatography, High Pressure Liquid; Drug Evaluation, Preclinical; In Vitro Techniques; Lipids; Male; Microdialysis; Pharmaceutical Preparations; Protein Binding; Rats; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine; Tissue Distribution | 2011 |
Species independence in brain tissue binding using brain homogenates.
Topics: Animals; Brain; Dogs; Guinea Pigs; Humans; Macaca fascicularis; Mice; Rats; Species Specificity | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Pharmacologic management of aggression and violence.
Topics: Adrenergic beta-Antagonists; Aggression; Antipsychotic Agents; Benzodiazepines; Carbamazepine; Contraindications; Delirium; Diagnosis, Differential; Humans; Lithium; Trazodone; Violence | 1992 |
Complex partial seizures in a patient receiving trazodone.
Topics: Carbamazepine; Depressive Disorder; Epilepsy, Temporal Lobe; Erectile Dysfunction; Humans; Male; Middle Aged; Trazodone | 1986 |
Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Carbamazepine; Female; Humans; Male; Middle Aged; Piperazines; Serotonin Receptor Agonists; Trazodone | 1996 |
Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression.
Topics: Aged; Anticonvulsants; Carbamazepine; Depressive Disorder; Drug Resistance; Drug Therapy, Combination; Female; Humans; Middle Aged; Selective Serotonin Reuptake Inhibitors; Trazodone | 1996 |
Interaction between trazodone and carbamazepine.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Carbamazepine; Depressive Disorder; Epilepsy, Complex Partial; Female; Fluorescence Polarization Immunoassay; Humans; Middle Aged; Trazodone | 1999 |
Probable interaction between trazodone and carbamazepine.
Topics: Aged; Anticonvulsants; Antidepressive Agents, Second-Generation; Antimanic Agents; Carbamazepine; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Humans; Trazodone; Treatment Outcome | 2011 |
A Transcriptome-Based Drug Discovery Paradigm for Neurodevelopmental Disorders.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Carbamazepine; Computer Simulation; Drug Discovery; Epirizole; Gene Expression Profiling; Gene Expression Regulation; Humans; Induced Pluripotent Stem Cells; MCF-7 Cells; Mice; Naloxone; Narcotic Antagonists; Neural Stem Cells; Neurodevelopmental Disorders; Neurons; PC-3 Cells; Perphenazine; Primary Cell Culture; Risperidone; RNA-Seq; Single-Cell Analysis; Transcriptome; Trazodone; Trimipramine | 2021 |